Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach.
Cisplatin, a platinating agent commonly used to treat several cancers, is associated with nephrotoxicity, neurotoxicity, and ototoxicity, which has hindered its utility. To gain a better understanding of the genetic variants associated with cisplatin-induced toxicity, we present a stepwise approach integrating genotypes, gene expression, and sensitivity of HapMap cell lines to cisplatin. Cell lines derived from 30 trios of European descent (CEU) and 30 trios of African descent (YRI) were used to develop a preclinical model to identify genetic variants and gene expression that contribute to cisplatin-induced cytotoxicity in two different populations. Cytotoxicity was determined as cell-growth inhibition at increasing concentrations of cisplatin for 48 h. Gene expression in 176 HapMap cell lines (87 CEU and 89 YRI) was determined using the Affymetrix GeneChip Human Exon 1.0 ST Array. We identified six, two, and nine representative SNPs that contribute to cisplatin-induced cytotoxicity through their effects on 8, 2, and 16 gene expressions in the combined, Centre d'Etude du Polymorphisme Humain (CEPH), and Yoruban populations, respectively. These genetic variants contribute to 27%, 29%, and 45% of the overall variation in cell sensitivity to cisplatin in the combined, CEPH, and Yoruban populations, respectively. Our whole-genome approach can be used to elucidate the expression of quantitative trait loci contributing to a wide range of cellular phenotypes.
Huang
R Stephanie
RS
Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
Duan
Shiwei
S
Shukla
Sunita J
SJ
Kistner
Emily O
EO
Clark
Tyson A
TA
Chen
Tina X
TX
Schweitzer
Anthony C
AC
Blume
John E
JE
Dolan
M Eileen
ME
D000970:Antineoplastic Agents / Q000633:toxicity*; D044383:Black People / Q000235:genetics; D002460:Cell Line; D002945:Cisplatin / Q000633:toxicity*; D015870:Gene Expression; D015894:Genome, Human; D005838:Genotype; D006801:Humans; D020128:Inhibitory Concentration 50; D020411:Oligonucleotide Array Sequence Analysis; D020641:Polymorphism, Single Nucleotide; D040641:Quantitative Trait Loci; D044465:White People / Q000235:genetics
D000970:Antineoplastic Agents; D002945:Cisplatin
Am J Hum Genet. 2000 Jan;66(1):279-92
10631157
Mol Cancer Ther. 2007 Jan;6(1):31-6
17237264
Nat Rev Cancer. 2003 Jul;3(7):517-25
12835671
Int J Clin Oncol. 2003 Jun;8(3):156-61
12851839
Mol Biol Cell. 2003 Jul;14(7):2876-89
12857871
Drugs. 2003;63(15):1549-63
12887262
Biostatistics. 2003 Apr;4(2):249-64
12925520
Curr Opin Otolaryngol Head Neck Surg. 2003 Oct;11(5):328-33
14502062
Oncogene. 2003 Oct 20;22(47):7265-79
14576837
Cancer Res. 2004 Jun 15;64(12):4353-6
15205351
Clin Cancer Res. 2004 Aug 1;10(15):4939-43
15297394
Radiat Res. 2004 Aug;162(2):128-35
15387139
Dan Med Bull. 1990 Feb;37(1):1-12
2178884
Crit Rev Oncol Hematol. 2005 Jan;53(1):3-11
15607931
Clin Cancer Res. 2005 Feb 15;11(4):1534-8
15746057
Nat Rev Drug Discov. 2005 Apr;4(4):307-20
15789122
Biochim Biophys Acta. 2005 Jun 30;1744(2):89-92
15950749
Chembiochem. 2005 Jul;6(7):1157-66
15934047
Clin Oncol (R Coll Radiol). 2005 Jun;17(4):249-57
15997920
Oncogene. 2005 Sep 8;24(40):6090-100
15940259
Nature. 2005 Oct 27;437(7063):1299-320
16255080
Biochem Pharmacol. 2006 Jan 12;71(3):239-47
16325149
J Biol Chem. 2005 Dec 30;280(52):42994-9
16157594
Int J Gynecol Cancer. 2006 Mar-Apr;16(2):690-7
16681749
Oncol Rep. 2006 Aug;16(2):381-7
16820919
Anticancer Drugs. 2007 Feb;18(2):161-70
17159602
J Cell Physiol. 2002 Jul;192(1):1-15
12115731